Identifying molecular targets for SARS-CoV-2 therapeutics.

Harvey Alter, Michael Houghton, and Charles Rice share the Physiology or Medicine award for their contributions to identifying the virus and demonstrating that it was responsible for hepatitis among blood transfusion recipients.

Repurposing Living Systems to Fight a Pandemic

Scientists rely on synthetic biology and cell-free expression systems for developing novel approaches to combat the pandemic.

Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.

Machine learning has pegged existing drugs to repurpose for COVID-19 clinical trials.

Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.

President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.

The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?